• The plant in Spain's Castilla-La Mancha region will undertake vial filling and packaging for AZD1222
• The company also provides drug substance manufacturing for AZD1222 through their site in Argentina
• Insud Pharma is at the forefront of Spanish companies in investment in R&D
mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America.
The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and mAbxience have obtained the “EXCELLENT” rating in the Profarma Plan 2019.
Exeltis USA, Inc. a division of the global pharmaceutical group Insud Pharma, announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Slynd™ (pronounced "slind") containing drospirenone 4 mg, an oral contraceptive tablet for pregnancy prevention.
•This award is recognition of the hard work and dedication of Silvia Gold, President of the Mundo Sano Foundation, in changing the course of Chagas disease.
•Mundo Sano is currently running the campaign Not a Single Baby with Chagas, to ensure that all babies and women of reproductive age have access to diagnosis and treatment.
•Chagas disease affects 8 million people worldwide. In Spain, there are estimated to be between 50,000 and 100,000 Chagas sufferers. Globally, almost 9,000 babies are born with Chagas disease every year.
Exeltis recently presented its manufacturing plant in Guatemala, located in Mixco’s zone 2, which formulates medicines for use in the areas of Women’s Health, Central Nervous System and Respiratory and Cardio Metabolic Diseases. The medicines manufactured are available in the domestic market and exported to the rest of Central America, the Dominican Republic, the Caribbean and Belize
Insud Pharma group have once again been rated “very good” in the 2018 edition of the Spanish government’s Profarma Programme, thanks to its industrial activity and commitment to R&D.
BioDan, a 3D dressing derived from human skin which can be bioprinted and frozen, Brainguard, a wearable system that predicts migraines, and Insulclock, a system which monitors and controls the treatment of diabetes patients are the three startups selected in the second round of the ChemoStart accelerator programme, which seeks to support innovative, disruptive solutions that improve people’s health and wellbeing.